Vaccines (Aug 2023)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen

  • Daniela Manno,
  • Catriona Patterson,
  • Abdoulie Drammeh,
  • Kevin Tetteh,
  • Mattu Tehtor Kroma,
  • Godfrey Tuda Otieno,
  • Bolarinde Joseph Lawal,
  • Seyi Soremekun,
  • Philip Ayieko,
  • Auguste Gaddah,
  • Abu Bakarr Kamara,
  • Frank Baiden,
  • Muhammed Olanrewaju Afolabi,
  • Daniel Tindanbil,
  • Kwabena Owusu-Kyei,
  • David Ishola,
  • Gibrilla Fadlu Deen,
  • Babajide Keshinro,
  • Yusupha Njie,
  • Mohamed Samai,
  • Brett Lowe,
  • Cynthia Robinson,
  • Bailah Leigh,
  • Chris Drakeley,
  • Brian Greenwood,
  • Deborah Watson-Jones

DOI
https://doi.org/10.3390/vaccines11081317
Journal volume & issue
Vol. 11, no. 8
p. 1317

Abstract

Read online

We assessed whether the immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen with a 56-day interval between doses was affected by exposure to malaria before dose 1 vaccination and by clinical episodes of malaria in the period immediately after dose 1 and after dose 2 vaccinations. Previous malaria exposure in participants in an Ebola vaccine trial in Sierra Leone (ClinicalTrials.gov: NCT02509494) was classified as low, intermediate, and high according to their antibody responses to a panel of Plasmodium falciparum antigens detected using a Luminex MAGPIX platform. Clinical malaria episodes after vaccinations were recorded as part of the trial safety monitoring. Binding antibody responses against the Ebola virus (EBOV) glycoprotein (GP) were measured 57 days post dose 1 and 21 days post dose 2 by ELISA and summarized as Geometric Mean Concentrations (GMCs). Geometric Mean Ratios (GMRs) were used to compare groups with different levels of exposure to malaria. Overall, 587 participants, comprising 188 (32%) adults (aged ≥ 18 years) and 399 (68%) children (aged 1–3, 4–11, and 12–17 years), were included in the analysis. There was no evidence that the anti-EBOV-GP antibody GMCs post dose 1 and post dose 2 differed between categories of previous malaria exposure. There was weak evidence that the GMC at 57 days post dose 1 was lower in participants who had had at least one episode of clinical malaria post dose 1 compared to participants with no diagnosed clinical malaria in the same period (GMR = 0.82, 95% CI: 0.69–0.98, p-value = 0.02). However, GMC post dose 2 was not reduced in participants who experienced clinical malaria post-dose 1 and/or post-dose 2 vaccinations. In conclusion, the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen is immunogenic in individuals with previous exposure to malaria and in those who experience clinical malaria after vaccination. This vaccine regimen is suitable for prophylaxis against Ebola virus disease in malaria-endemic regions.

Keywords